ANIMAL NMR AND RADIONUCLIDE IMAGING

动物核磁共振和放射性核素成像

• 批准号: 2906994
• 负责人: JASON Arthur KOUTCHER
• 金额: $ 114.52万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2906994
• 关键词: Primates; Rodentias; autoradiography; bioimaging /biomedical imaging; biomedical equipment development; biomedical equipment resource; dogs; drug screening /evaluation; image processing; neoplasm /cancer radionuclide diagnosis; neoplasm /cancer radionuclide therapy; nuclear magnetic resonance spectroscopy; positron emission tomography; radiopharmacology; radiotracer; swine

Research at Memorial Sloan Kettering Cancer Center is focused on cancer diagnosis and enhancing responses of tumor to treatment with a goal of curing cancer. Animal studies of novel cancer therapeutics, while imperfect as a treatment model, have utility, both in studying therapeutic efficacy and toxicity. Because tumors are heterogenous, both between individuals and within a single tumor, non-invasive imaging studies are necessary to provide information about variation in response. We propose to use three imaging technologies, nuclear magnetic resonance (NMR), positron emission tomography (PET), and quantitative autoradiography (QAR) to study a diverse range of topics that relate to cancer treatment. The three imaging techniques chosen were based on the fact that they are closely related. PET and QAR studies are synergistic, since QAR can be used to screen and evaluate new compounds that may be potential radiopharmaceuticals for PET. QAR and NMR both can evaluate blood flow and vascular permeability. PET and NMR can be used to investigate tumor metabolism, and clinically are often used in a complementary manner. The range of projects studied include predicting tumor response to treatment, dosimetry for radioimmunotherapy, pharmacology, gene therapy, tumor metabolism, and evaluating responses to novel cytostatic agents. In particular, we have focused on novel treatments, such as gene therapy, new "designer" drugs that are undergoing early clinical trials but lack endpoints since they are cytostatic. An important component of this research effort is in the imaging development effort. NMR studies will focus on designing better radiofrequency probes, enhancing spectral resolution, quantitation and image processing. PET research focuses on modeling, particularly of radiolabeled monoclonal antibodies, image processing and spatial registration. Dr. Blasberg will extend his previous novel developments in QAR and use 4 isotopes to study 4 different physiologic or biochemical processes within a tumor concurrently. Leadership will come from the imaging scientists (Drs. Koutcher, Blasberg and Larson) and also from the molecular pharmacology group. Monthly meetings between these two groups are viewed as essential to decide which problems are important and appropriate to be addressed by imaging technology. A Technology Committee also evaluate new imaging technologies for consideration.

纪念斯隆·凯特琳癌症中心的研究重点是癌症诊断和增强肿瘤对治疗的反应，目标是治愈癌症。新的癌症治疗方法的动物实验虽然作为一种治疗模式并不完美，但在研究治疗效果和毒性方面都是有用的。由于肿瘤是异质性的，无论是个体之间还是单个肿瘤内，非侵入性成像研究都是必要的，以提供有关反应变异的信息。我们建议使用三种成像技术，核磁共振(核磁共振)、正电子发射断层扫描(PET)和定量放射自显影(QAR)来研究与癌症治疗相关的各种主题。选择这三种成像技术是基于它们密切相关的事实。PET和QAR研究是协同的，因为QAR可以用于筛选和评估可能成为PET潜在放射性药物的新化合物。QAR和核磁共振均可评价血流和血管通透性。PET和核磁共振可用于研究肿瘤代谢，在临床上常以互补的方式使用。研究的项目范围包括预测肿瘤对治疗的反应、放射免疫治疗的剂量学、药理学、基因治疗、肿瘤代谢以及评估对新型细胞抑制剂的反应。特别是，我们将重点放在新的治疗方法上，例如基因疗法，即正在进行早期临床试验但由于具有细胞抑制作用而缺乏终点的新型“设计”药物。这项研究工作的一个重要组成部分是成像开发工作。核磁共振研究将集中在设计更好的射频探头，提高光谱分辨率，定量和图像处理。PET研究的重点是建模，特别是放射性标记的单抗、图像处理和空间配准。布拉斯伯格博士将扩展他之前在QAR方面的新进展，并使用4种同位素同时研究肿瘤内的4种不同的生理或生化过程。领导将来自成像科学家(Koutcher、Blasberg和Larson博士)以及分子药理学小组。这两个小组之间的每月会议被视为决定哪些问题是重要的，以及哪些问题适合通过成像技术解决的关键。技术委员会还评估新的成像技术以供考虑。